Literature DB >> 23271108

A genomic analysis of Clostridium difficile infections in blunt trauma patients.

Philip Alexander Efron1, Huazhi Liu, Lawrence Lottenberg, Alex Gervacio Cuenca, Lori Filichia Gentile, Makesha Vernee Miggins, Azra Bihorac, Henry V Baker, Frederick Alan Moore, Lyle Linc Moldawer, Darwin N Ang.   

Abstract

BACKGROUND: Evidence demonstrates that susceptibility to Clostridium difficile infection is related to host risk factors as much as bacterial potency. Using blood leukocyte genome-wide expression patterns of severe blunt trauma patients obtained by the National Institute of General Medical Sciences-sponsored Glue Grant Inflammation and the Host Response to Injury, we examined leukocyte genomic profiles of patients with C. difficile infection to determine preinfection and postinfection gene expression changes.
METHODS: The genomic responses of 21 severe trauma patients were analyzed (5 C. difficile, 16 controls matched for age and severity of injury). After elimination of probe sets whose expression was below baseline or were unchanged, remaining probe sets underwent hierarchical clustering and principal component analysis. Molecular pathways were generated through Ingenuity Pathways Analysis.
RESULTS: Supervised analysis demonstrated 118 genes whose expression in patients with C. difficile infection varied before and after their infection. Supervised analysis comparing patients with C. difficile infection with matched non-C. difficile patients before infection suggested that the expression of 501 genes were different in the two groups with up to 87% class prediction (p < 0.05). Many of these genes are related to cell-mediated immune responses, signaling, and interaction.
CONCLUSION: Genomic analysis of severe blunt trauma patients reveals a distinct leukocyte expression profile of C. difficile both before and after infection. We conclude that an association may exist between a severe trauma patient's leukocyte genomic expression profile and subsequent susceptibility to C. difficile infection. Further prospective expression analysis of this C. difficile population may reveal potential therapeutic interventions and allow early identification of C. difficile-susceptible patients. LEVEL OF EVIDENCE: Prognostic/diagnostic study, level III.

Entities:  

Mesh:

Year:  2013        PMID: 23271108      PMCID: PMC3864116          DOI: 10.1097/TA.0b013e3182789426

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  11 in total

1.  Clostridium difficile colitis.

Authors:  Philip A Efron; John E Mazuski
Journal:  Surg Clin North Am       Date:  2009-04       Impact factor: 2.741

Review 2.  Clostridium difficile--more difficult than ever.

Authors:  Ciarán P Kelly; J Thomas LaMont
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

3.  Inflammation and the Host Response to Injury, a large-scale collaborative project: Patient-Oriented Research Core--standard operating procedures for clinical care. I. Guidelines for mechanical ventilation of the trauma patient.

Authors:  Avery B Nathens; Jeffrey L Johnson; Joseph P Minei; Ernest E Moore; Michael Shapiro; Paul Bankey; Brad Freeman; Brian G Harbrecht; Stephen F Lowry; Bruce McKinley; Fredrick Moore; Michael West; Ronald V Maier
Journal:  J Trauma       Date:  2005-09

4.  Clostridium difficile-associated disease acquired in the neurocritical care unit.

Authors:  S A Musa; H Robertshaw; S J Thomson; M L Cowan; T M Rahman
Journal:  Neurocrit Care       Date:  2010-08       Impact factor: 3.210

5.  A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection.

Authors:  Kevin W Garey; Zhi-Dong Jiang; Shashank Ghantoji; Vincent H Tam; Vaneet Arora; Herbert L Dupont
Journal:  Clin Infect Dis       Date:  2010-11-08       Impact factor: 9.079

6.  Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.

Authors:  L Kyne; M Warny; A Qamar; C P Kelly
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

7.  Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2005-12-02       Impact factor: 17.586

8.  Clostridium difficile infection in critically injured trauma patients.

Authors:  Kimberly Lumpkins; Grant V Bochicchio; Manjari Joshi; Ryan Gens; Kelly Bochicchio; Anne Conway; Stacey Schaub; Thomas Scalea
Journal:  Surg Infect (Larchmt)       Date:  2008-10       Impact factor: 2.150

9.  Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea.

Authors:  Zhi-Dong Jiang; Kevin W Garey; Margaret Price; Gail Graham; Pablo Okhuysen; Thanh Dao-Tran; Mark LaRocco; Herbert L DuPont
Journal:  Clin Gastroenterol Hepatol       Date:  2007-07-06       Impact factor: 11.382

10.  Identification and interpretation of longitudinal gene expression changes in trauma.

Authors:  Natasa Rajicic; Joseph Cuschieri; Dianne M Finkelstein; Carol L Miller-Graziano; Douglas Hayden; Lyle L Moldawer; Ernest Moore; Grant O'Keefe; Kimberly Pelik; H Shaw Warren; David A Schoenfeld
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

View more
  2 in total

1.  Clostridium difficile Infections after Blunt Trauma: A Different Patient Population?

Authors:  Erin L Vanzant; Tezcan Ozrazgat-Baslanti; Huazhi Liu; Seemab Malik; Ruth Davis; Jennifer Lanz; Makesha V Miggins; Lori F Gentile; Angela Cuenca; Alex G Cuenca; Lawrence Lottenberg; Frederick A Moore; Darwin N Ang; Azra Bihorac; Philip A Efron
Journal:  Surg Infect (Larchmt)       Date:  2015-06-02       Impact factor: 2.150

Review 2.  The Use of Multiplexing to Identify Cytokine and Chemokine Networks in the Immune-Inflammatory Response to Trauma.

Authors:  Jillian Bonaroti; Sultan Abdelhamid; Upendra Kar; Jason Sperry; Ruben Zamora; Rami Ahmd Namas; Todd McKinley; Yoram Vodovotz; Timothy Billiar
Journal:  Antioxid Redox Signal       Date:  2021-05-19       Impact factor: 7.468

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.